US stock · Healthcare sector · Diagnostics & Research
Company Logo

CareDx, Inc

CDNANASDAQ

25.86

USD
+0.71
(+2.82%)
Market Closed
-27.63P/E
431Forward P/E
-1.07P/E to S&P500
1.376BMarket CAP
- -Div Yield
Upcoming Earnings
27 Jul-1 Aug
Shares Short
4/29/22
4.42M
Short % of Float
8.46%
Short % of Shares Outs.
8.31%
% Held by Insiders
1.81%
% Held by Institutions
104.12%
Beta
0.79
PEG Ratio
-2.93
52w. high/low
96.88/21.25
Avg. Daily Volume
0.82M
Return %
Stock
S&P 500
1 year
(65.17)
(6.46)
3 years
(22.34)
36.32
5 years
2410.68
63.92
Scale: |
High
Low
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
10.89
5.40
8.00
3.70
6.84
2.50
7.98
0.76
30.80
4.92
41.27
18.75
79.92
13.04
99.83
39.16
47.82
21.27
Currency: USD
- -
- -
- -
- -
- -
- -
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
TTM
Revenue per share
- -
- -
- -
- -
- -
- -
2.77
3.00
4.70
2.37
2.46
2.07
2.15
3.01
4.13
5.63
5.86
Earnings per share
- -
- -
- -
- -
- -
- -
(0.69)
(0.48)
0.13
(1.16)
(2.39)
(2.38)
(1.31)
(0.52)
(0.40)
(0.58)
(0.95)
FCF per share
- -
- -
- -
- -
- -
- -
(0.26)
(0.09)
(0.70)
(0.92)
(1.03)
(0.62)
(0.32)
(0.15)
0.50
(0.75)
(0.63)
Dividends per share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
CAPEX per share
- -
- -
- -
- -
- -
- -
0.02
0.01
0.13
0.10
0.03
0.01
0.20
0.08
0.22
0.38
0.50
Book Value per sh.
- -
- -
- -
- -
- -
- -
(19.97)
(20.44)
7.10
2.49
1.18
(0.26)
2.69
2.35
5.97
8.84
8.90
Comm.Shares outs.
- -
- -
- -
- -
- -
- -
7
7
6
12
16
23
36
42
46
53
53
Avg. annual P/E ratio
- -
- -
- -
- -
- -
- -
- -
- -
60.0
(5.1)
(1.9)
(1.3)
(11.9)
(54.5)
(87.1)
(122.0)
(27.6)
P/E to S&P500
- -
- -
- -
- -
- -
- -
- -
- -
3.3
(0.3)
(0.1)
(0.1)
(0.5)
(2.2)
(2.3)
(4.1)
(1.1)
Avg. annual div. yield
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue (m)
- -
- -
- -
- -
- -
- -
20
22
27
28
41
48
77
127
192
296
308
Operating margin
- -
- -
- -
- -
- -
- -
(11.5)%
(3.9)%
4.6%
(42.4)%
(91.9)%
(42.0)%
(20.3)%
(19.3)%
(11.7)%
(10.0)%
(15.3)%
Depreciation (m)
- -
- -
- -
- -
- -
- -
1
1
1
1
3
4
4
6
10
12
13
Net profit (m)
- -
- -
- -
- -
- -
- -
(5)
(4)
1
(14)
(39)
(55)
(47)
(22)
(19)
(31)
(50)
Income tax rate
- -
- -
- -
- -
- -
- -
- -
- -
208.6%
- -
3.9%
3.0%
3.0%
8.3%
5.2%
4.4%
2.9%
Net profit margin
- -
- -
- -
- -
- -
- -
(24.7)%
(16.0)%
2.9%
(48.7)%
(97.1)%
(114.8)%
(61.1)%
(17.3)%
(9.7)%
(10.3)%
(15.9)%
Working capital (m)
- -
- -
- -
- -
- -
- -
1
1
29
24
(14)
(16)
62
37
204
356
345
Long-term debt (m)
- -
- -
- -
- -
- -
- -
13
11
5
13
1
18
- -
- -
16
17
17
Equity (m)
- -
- -
- -
- -
- -
- -
(147)
(151)
41
29
19
(6)
96
99
278
466
458
ROIC
- -
- -
- -
- -
- -
- -
(68.5)%
(61.1)%
(3.0)%
(26.6)%
(105.8)%
(123.0)%
(38.8)%
(18.8)%
(6.3)%
(6.3)%
(10.3)%
Return on capital
- -
- -
- -
- -
- -
- -
(23.9)%
(14.1)%
2.3%
(21.8)%
(51.3)%
(61.5)%
(34.0)%
(15.8)%
(5.4)%
(5.7)%
(9.3)%
Return on equity
- -
- -
- -
- -
- -
- -
3.4%
2.4%
1.9%
(46.5)%
(202.6)%
904.3%
(48.7)%
(22.2)%
(6.7)%
(6.6)%
(10.8)%
Plowback ratio
- -
- -
- -
- -
- -
- -
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
100.0%
Div.&Repurch./FCF
- -
- -
- -
- -
- -
- -
- -
- -
961.2%
- -
- -
- -
- -
- -
- -
- -
- -
Capital Structure
5 May · 2022 | Q1
All numbers in millions
Total liabilities
$ 89
Total assets
$ 547
Long-term debt
$ 17
Cash and equiv.
$ 172
Goodwill
$ 37
Retained earnings
$ (403)
Common stock
53
Enterprise Value
$ 1,221
Working Capital
Currency: USD, in millions
2019
2020
2021
Cash & Investments
38
225
348
Receivables
24
35
60
Inventory
6
10
17
Other
4
100
318
Current assets
72
273
433
Acc. Payable
6
10
13
Debt due
3
2
4
Other
26
58
60
Current liabilities
35
69
77
Annual growth rates
(avg. rate of change)
1 year
5 years
10 years
Revenue
54.22%
57.47%
36.43%
Cash flow
(271.44)%
(204.14)%
(15.55)%
Earnings
63.85%
(4.92)%
(199.81)%
Dividends
- -
- -
- -
Book value
67.78%
(353.10)%
(192.39)%
Insider Trading
Type
Shares
Date
Colon Grace
Sale
5,179
05/11/22
Bickerstaff George
Award
223
05/09/22
Cournoyer Christine
Award
100
05/09/22
Goldberg Michael
Exempt
500
04/11/22
Goldberg Michael
Sale
500
04/11/22
Quarterly Revenue
Currency: USD, in millions
Year
1Q
2Q
3Q
4Q
Total
2020
38
42
53
59
192
2021
67
74
76
79
296
2022
79
- -
- -
- -
- -
Earnings per share
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
(0.13)
(0.14)
(0.06)
(0.08)
(0.40)
2021
(0.01)
(0.04)
(0.23)
(0.31)
(0.58)
2022
(0.37)
- -
- -
- -
- -
Quarterly dividends paid
Currency: USD
Year
1Q
2Q
3Q
4Q
Total
2020
- -
- -
- -
- -
- -
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
Company Description
Sector:
Healthcare
Industry:
Diagnostics & Research
CEO:
Dr. Peter Maag
Full-time employees:
633
City:
South San Francisco
Address:
1 Tower Place, 9Th Floor
IPO:
Jul 17, 2014
Website:
CareDx, Inc. discovers, develops, and commercializes diagnostic solutions for transplant patients and caregivers worldwide. It provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company also offers TruSight HLA, a next generation sequencing (NGS) based high resolution typing solution; Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; and XynQAPI transplant quality tracking and waitlist management solutions, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.